Recovery starts with VERIS™

Prescribed by clinicians, applied by patients.

VERIS™ is an advanced wound care product made with a collagen derivative + certified Mānuka honey + hydroxyapatite. VERIS™ is designed to help patients recover from wounds in an average of 4-8 weeks (1-4*). It’s FDA-cleared, covered by Medicare and most commercial plans, and built to make post-Mohs recovery easy for clinics and empowering for patients.

* SweetBio®'s core technology, MX®, has been clinically evaluated and accepted as a skin substitute / Cellular and Tissue-Based Product (CTP). This technology composition has been translated to VERIS™.

Discover the VERIS™ difference

Request a Sample

Request in-service

Submit Case Study

Case Book

Evidence

For Clinicians

Press

1. Rodriguez et al. Novel bioengineered collagen + Manuka honey + hydroxyapatite sheet for the treatment of lower extremity chronic wounds in an urban hospital wound care setting. 2023.

2. Rodriguez et al. Preliminary clinical evaluation of a novel bioengineered wound product: A focus on the management of lower extremity ulcers. 2020.

3. McMurray et al. Use of a Novel Biomaterial to Enhance Secondary Intention Healing. 2021.

4. Arnaud et al. Novel Biomaterial Containing Gelatin, Manuka Honey, and Hydroxyapatite Enhanced Secondary Intention Healing Versus Standard Secondary Intention Healing in Mohs Surgical Defects on the Head and Distal Lower Extremities-A Randomized Controlled Trial: Pilot Study. 2023.

5. Williams et al. A novel bioengineered wound product with in vitro capabilities to reduce bacteria. 2021.

6. Rodriguez et al. Microenvironment influence of a novel bioengineered wound product APIS®: An in vitro analysis of inflammatory marker and growth factor secretion. 2021.

7. Rodriguez et al. A Preliminary Direct Comparison of the Inflammatory Reduction and Growth Factor Production Capabilities of Three Commercially Available Wound Products: Collagen Sheet, Manuka Honey Sheet, and a Novel Bioengineered Collagen Derivative + Manuka Honey + Hydroxyapatite Sheet. 2022.

8. Dantas et al. 2011; Li et al. 2014; Pezeshki-Modaress et al. 2014; Pezeshki-Modaress et al. 2015

9. Sell et al. 2012; Afrin et al. 2018; Johnston et al. 2018; Minden-Birkenmaier et al. 2018

10. Okabayashi et al. 2009; Majeed et al. 2012; Kawai et al. 2011; Weilin et al. 2016; Tommila et al.2008; Vilardell et al. 2016; Rodriguez et al. 2013 & 2016

* Based on clinical and in vitro data; claims have not been cleared by the FDA. Faster wound closure reported in slower healing and chronic wounds compared to standard of care.

LEARN

Press

Terms of Service

Privacy + Cookie Policy

© 2026 SweetBio® Inc.